stockrow
Friday 6 November 2026
Export EMBC’s income statement to Excel — free account
Embecta Corp.
EMBC Healthcare Medical Instruments & Supplies
Embecta Corp.’s revenue for fiscal 2025 (year ended September 2025) was $1.1 billion, down 3.80% from fiscal 2024.
- Revenue
- −8.05%
- EPS
- −53.9%
- Free cash flow
- −49.6%
- Total debt
- −1.00%
Quarter to June 2026, against a year earlier
6.14
0.19
−3.00%
Follow EMBC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to September
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 1,109 | 285 | 289 | 1,130 | 1,121 | 1,123 | 1,080 | 1,019 | (0.4%) | 1,024 | 1,082 | 1,087 | +0.2% | |
| Gross margin, % | — | — | — | 70.87 | 67.05 | 70.48 | 68.61 | 66.91 | 65.46 | 62.64 | 59.03 | (8.2) pt | ||||||
| EBT | — | — | — | 500 | 125 | 117 | 257 | 106 | 44 | 136 | 125 | (19.5%) | ||||||
| EBT margin, % | — | — | — | 45.09 | 43.85 | 40.30 | 22.72 | 9.43 | 3.94 | 12.62 | 12.27 | (32.5) pt | ||||||
| Net income | — | 0 | — | 432 | 105 | 99 | 224 | 70 | 78 | 95 | 88 | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 19.81 | 19.58 | 19.47 | 18.53 | 17.42 | n/m | |||||
| Earnings | — | — | — | — | 7.50 | 7.28 | 3.92 | 1.23 | 1.36 | 1.64 | 1.49 | (26.2%) | ||||||
| Cash flow | — | — | — | 0.00 | 0.00 | 0.00 | 7.23 | 1.18 | 0.62 | 3.29 | 2.98 | n/m | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | (0.42) | (0.46) | (0.27) | (0.16) | 0.01 | n/m | ||||||
| Free cash flow | — | — | — | 0.00 | 0.00 | 0.00 | 6.81 | 0.72 | 0.35 | 3.13 | 2.99 | n/m | ||||||
| Book value | — | — | — | — | 0.00 | 0.00 | (15.63) | (14.35) | (12.80) | (11.16) | (10.48) | n/m | ||||||
| Shares, m | — | — | — | — | 57 | 57 | 57 | 57 | 58 | 58 | 59 | +0.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 5.22 | 5.22 | 5.22 | 7.40 | 11.94 | 10.44 | 8.66 | 4.24 | 7.7 | |||||
| P/S | — | — | — | 2.29 | 2.29 | 2.29 | 1.45 | 0.75 | 0.72 | 0.76 | 0.36 | 1.5 | ||||||
| P/B | — | — | — | 4.87 | 4.87 | 4.87 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.1 | ||||||
| EV/Sales | — | — | — | 2.29 | 2.29 | 2.29 | 2.61 | 1.92 | 1.91 | 1.87 | 1.60 | 2.2 | ||||||
| EV/FCF | — | — | — | 6.07 | 6.07 | 6.07 | 7.61 | 52.17 | 107.74 | 11.08 | 9.35 | 28.1 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | 505 | 121 | 139 | 412 | 68 | 36 | 192 | 174 | (14.9%) | |||||
| Capex | — | — | — | (69) | (11) | (4) | (24) | (26) | (16) | (9) | 1 | (28.4%) | ||||||
| Free cash flow | — | — | — | 505 | 110 | 135 | 388 | 41 | 20 | 182 | 175 | (15.6%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 98 | 99 | 364 | 396 | 387 | 370 | 285 | +30.4% | |||||
| Net debt | — | — | — | — | 5 | 4 | 1,309 | 1,308 | 1,331 | 1,198 | 1,264 | +199.2% | ||||||
| Shareholders’ equity | — | — | — | — | — | 551 | (891) | (822) | (738) | (651) | (613) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | 0.00 | 12.93 | 24.49 | 6.12 | 6.26 | 8.03 | 7.22 | +8.0 pt | |||||
| ROIC | — | — | — | — | 0.00 | 13.24 | 46.30 | 28.44 | 17.59 | 27.63 | 21.44 | +27.6 pt | ||||||
| ROE | — | — | — | 0.00 | 0.00 | 17.26 | (131.18) | (8.22) | (10.04) | (13.74) | (13.65) | (13.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 1,900 | 2,200 | 2,100 | 1,850 | — | (0.9%) | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.59 | 0.51 | 0.53 | 0.58 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Sep 2025 · latest quarter Jun 2026
Embecta Corp. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NNNN Anbio Biotechnology | $516.6M | — | — | — | — | — | — | — | Compare |
| ZJYL Jin Medical International Ltd. | $509.4M | — | — | — | — | −8,074.17% (below 0%: shrinking) | 34.44% | 0.00% | Compare |
| ANGO AngioDynamics, Inc. | $496.7M | — (loss-making) | — (loss-making) | +6.87% (above 0%: growing) | n/m | +5.62% (above 0%: growing) | 59.37% | (9.02%) | Compare |
| EMBC Embecta Corp. | $358.7M | 4.2× | 5.3× | −8.05% (below 0%: shrinking) | −53.85% (below 0%: shrinking) | −49.63% (below 0%: shrinking) | 56.42% | 17.92% | |
| SMTI Sanara MedTech Inc. | $290.4M | — (loss-making) | 164× | +9.04% (above 0%: growing) | n/m | +131.28% (above 0%: growing) | 92.96% | 6.33% | Compare |
| OSUR OraSure Technologies, Inc. | $232.4M | — (loss-making) | — (loss-making) | −1.93% (below 0%: shrinking) | n/m | −1.40% (below 0%: shrinking) | 43.46% | 17.76% | Compare |
| UTMD Utah Medical Products, Inc. | $202.4M | 21.7× | 28.7× | −14.31% (below 0%: shrinking) | −10.64% (below 0%: shrinking) | −55.74% (below 0%: shrinking) | 55.79% | 31.06% | Compare |
| PDEX Pro-Dex, Inc. | $195.8M | 16.4× | 18.8× | +10.96% (above 0%: growing) | −33.57% (below 0%: shrinking) | +177.76% (above 0%: growing) | 33.35% | 17.10% | Compare |
| KRMD KORU Medical Systems, Inc. | $139.9M | — (loss-making) | — (loss-making) | +18.15% (above 0%: growing) | n/m | +26.17% (above 0%: growing) | 65.14% | 5.21% | Compare |
| Median of peers | $261.4M | — | 28.7× | +7.96% | — | +5.62% | 55.79% | 6.33% |
Pay and ownership Proxy statement filed 18 December 2025
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 9.40m | 8.71m | 51.78 |
| 2024 | 8.59m | 7.42m | 49.55 |
| 2023 | 7.46m | (1.28m) | 50.82 |
| 2022 | 11.25m | 11.14m | 94.82 |
Ownership
Directors and executive officers, together
1.30%
BlackRock, Inc.
14.80%
The Vanguard Group
9.00%
Entities affiliated with American Century Investment Management, Inc.
8.80%
River Road Asset Management, LLC
5.60%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement